NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced a two-day summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, August 18, and Wednesday, August 19, 2020, beginning at 1:00 p.m. ET each day.
Registration links and webcast information:Please click here to register for the event on Tuesday, August 18, 2020.Please click here to register for the event on Wednesday, August 19, 2020.Following each event, the webcast will be available on the News / Events page, located within the Investors section of Fortress’ website, https://www.fortressbiotech.com/news-media/events, for approximately 30 days.Agenda:Day One: Tuesday, August 18, 2020Opening Remarks – 1 p.m. ETLindsay Rosenwald, M.D., Chairman, President & CEOPanel #1 – 1:20 p.m. ET: Journey Medical CorporationClaude Maraoui, President & CEO; Robert Nevin, CCO; Nirav Jhaveri, CFOPanel #2 – 1:50 p.m. ET: Cyprium TherapeuticsLung Yam, M.D., Ph.D., President & CEO; Charles Buchen, M.D., Vice President, Business Development
Stephen G. Kaler, M.D., M.P.H., Professor of Pediatrics and Genetics and a physician-scientist in the Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children’s HospitalPanel #3 – 2:20 p.m. ET: Avenue Therapeutics (ATXI)Lucy Lu, M.D., President & CEO; Joseph Vazzano, CFO
Neil Singla, M.D., Chief Scientific Officer, Lotus Clinical Research, LLCPanel #4 – 2:50 p.m. ET: Mustang Bio (MBIO) – Gene TherapyManuel Litchman, M.D., President & CEO
Harry L. Malech, M.D., Chief, Genetic Immunotherapy Section, National Institute of Allergy and Infectious Diseases, NIHDay Two: Wednesday, August 19, 2020 Oncology Strategy Overview – 1 p.m. ETLindsay Rosenwald, M.D., Chairman, President & CEOPanel #1 – 1:20 p.m. ET: Mustang Bio (MBIO) – Cancer Cell TherapyManuel Litchman, M.D., President & CEO
Stephen J. Forman, M.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation;
Director, T Cell Therapeutics Research Laboratory, City of HopePanel #2 – 1:50 p.m. ET: Checkpoint Therapeutics (CKPT)James F. Oliviero, President & CEO
David M. Miller, M.D., Ph.D., Dermatologist and Medical Oncologist at Massachusetts General HospitalPanel #3 – 2:20 p.m. ET: OncogenuityArthur Ross, Chief Business Officer
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was recently ranked number 10 in Deloitte’s 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. For more information, visit www.fortressbiotech.com.Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.Company Contacts:
Jaclyn Jaffe and William Begien
Fortress Biotech, Inc.
(781) 652-4500
[email protected]Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]
Bay Street News
